Ultrasound Guided Octreotide LAR Injection in Acromegaly
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Approximately half of patients with acromegaly do not respond to treatment with somatostatin
receptor ligands such as octreotide LAR. This may be due to inadequate drug delivery if the
standard of care regular injection is inaccurately delivered in the intramuscular (IM)
compartment. Ultrasound guidance of IM injections may improve accuracy of placement of IM
injections and increase drug levels, thereby improving efficacy of octreotide LAR for the
treatment of acromegaly. The purpose of this study is to determine whether octreotide LAR
drug levels differ if given by ultrasound-guided IM injection or by regular IM injection in
patients with acromegaly.